Zobrazeno 1 - 10
of 281
pro vyhledávání: '"R. Macon"'
Autor:
Sanjal H. Desai, Levi Pederson, Betsy LaPlant, Raphael Mwangi, Matthew Maurer, Jason R. Young, William R. Macon, Rebecca L. King, Yucai Wang, James R. Cerhan, Andrew Feldman, David J. Inwards, Ivana Micallef, Patrick Johnston, Luis F. Porrata, Stephen M. Ansell, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 5, Pp 1-6 (2022)
Abstract Studies evaluating Positron Emission Tomography scan after 2 cycles of chemotherapy (PET2) in newly diagnosed diffuse large B cell lymphoma (DLBCL) are heterogeneous in patient characteristics, treatments and have conflicting results. Here w
Externí odkaz:
https://doaj.org/article/78c8b113aa5c400095ef1c63894b6828
Autor:
Sanjal H. Desai, Betsy LaPlant, William R. Macon, Rebecca L. King, Yucai Wang, David J. Inwards, Ivana Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 9, Pp 1-7 (2021)
Abstract Diffuse large B-cell lymphoma (DLBCL), either concurrent with or transformed from follicular lymphoma (FL) is often excluded from clinical trials. Lenalidomide has response rates of 45% in relapsed transformed DLBCL. Herein we present an ana
Externí odkaz:
https://doaj.org/article/f4212dffb29c4151bf80a173ed91804d
Autor:
Arushi Khurana, Raphael Mwangi, Stephen M. Ansell, Thomas M. Habermann, James R. Cerhan, Christopher Strouse, Brian K. Link, Yucai Wang, Rebecca L. King, William R. Macon, J. C. Villasboas, Thomas E. Witzig, Matthew J. Maurer, Grzegorz S. Nowakowski
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 7, Pp 1-6 (2021)
Abstract Immediate treatment for asymptomatic, low-tumor burden follicular lymphoma (FL) has not shown an overall survival benefit over “watch and wait” (W/W) strategy. We estimated incidence of treatment initiation at specific time points and as
Externí odkaz:
https://doaj.org/article/2ab24d0ad1894000ad27df5d6466a040
Autor:
Rebecca L. King, Arushi Khurana, Raphael Mwangi, Angelo Fama, Kay M. Ristow, Matthew J. Maurer, William R. Macon, Stephen M. Ansell, N. Nora Bennani, Yogish C. Kudva, Randall C. Walker, Kymberly D. Watt, Thomas R. Schwab, Sudhir S. Kushwaha, James R. Cerhan, Thomas M. Habermann
Publikováno v:
HemaSphere, Vol 5, Iss 10, p e640 (2021)
The World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues (WHO 2017) included updated criteria for diagnosis and classification of post-transplant lymphoproliferative disorders (PTLDs). This study evaluated the cl
Externí odkaz:
https://doaj.org/article/a7bccd95c6bf4844b0f3cdb75c6fe38f
Autor:
Stephanie L Skala, Jing C Ye, Jennifer Stumph, William R Macon, Frances R Quinones, Vadim Khachaturov, Rhett P Ketterling, Rajan Dewar
Publikováno v:
Clinical Pathology, Vol 12 (2019)
We report an index case of histiocytic sarcoma arising in a 70-year-old patient with long-standing chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The patient presented in 2017 with painful, enlarging swelling of the left neck. He
Externí odkaz:
https://doaj.org/article/314911cc96a5455fabee0dfec9b00001
Autor:
Ellen D. McPhail, Matthew J. Maurer, William R. Macon, Andrew L. Feldman, Paul J. Kurtin, Rhett P. Ketterling, Rakhee Vaidya, James R. Cerhan, Stephen M. Ansell, Luis F. Porrata, Grzegorz S. Nowakowski, Thomas E. Witzig, Thomas M. Habermann
Publikováno v:
Haematologica, Vol 103, Iss 11 (2018)
High-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements (double-/triple-hit lymphoma) have an aggressive clinical course. We investigated the prognostic value of transformation from low-grade lymphoma, cytological features (high grad
Externí odkaz:
https://doaj.org/article/51bf1a7568c5469893dfbff05911e177
Autor:
Randy D. Gascoyne, Sandra J. Horning, John C. Reed, Ari Melnick, Edie A. Weller, James K. Weick, L. Jeffrey Medeiros, Eric D. Hsi, Raymond E. Felgar, Mukesh Chhanabhai, William R. Macon, Richard I. Fisher, Thomas M. Habermann, Lijun Zhang, Maryla Krajewska, Beverly Nelson, Daina Variakojis, Vikas Aurora, Shuli Li, Jane N. Winter
Purpose: To prospectively investigate the prognostic significance of p21 and p53 expression in diffuse large B-cell lymphoma in the context of the U.S. Intergroup trial comparing conventional cyclophosphamide, doxorubicin, vincristine, and prednisone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::978c7e7322d2e9d00bdb5457c09b976c
https://doi.org/10.1158/1078-0432.c.6517330.v1
https://doi.org/10.1158/1078-0432.c.6517330.v1
Publikováno v:
Journal of Pathology Informatics, Vol 11, Iss 1, Pp 16-16 (2020)
Externí odkaz:
https://doaj.org/article/08dfc890f09c4164b023a2d9b760f2ca
Autor:
Betsy LaPlant, Thomas M. Habermann, Ivana N. Micallef, Luis F. Porrata, Rebecca L. King, Yucai Wang, Stephen M. Ansell, William R. Macon, Patrick B. Johnston, David J. Inwards, Thomas E. Witzig, Sanjal Desai, Grzegorz S. Nowakowski
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 9, Pp 1-7 (2021)
Blood Cancer Journal
Blood Cancer Journal
Diffuse large B-cell lymphoma (DLBCL), either concurrent with or transformed from follicular lymphoma (FL) is often excluded from clinical trials. Lenalidomide has response rates of 45% in relapsed transformed DLBCL. Herein we present an analysis of
Autor:
Yucai Wang, Arushi Khurana, Thomas M. Habermann, Jose C. Villasboas, Brian K. Link, William R. Macon, Stephen M. Ansell, Matthew J. Maurer, Raphael Mwangi, James R. Cerhan, Rebecca L. King, Christopher Strouse, Grzegorz S. Nowakowski, Thomas E. Witzig
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 7, Pp 1-6 (2021)
Blood Cancer Journal
Blood Cancer Journal
Immediate treatment for asymptomatic, low-tumor burden follicular lymphoma (FL) has not shown an overall survival benefit over “watch and wait” (W/W) strategy. We estimated incidence of treatment initiation at specific time points and assessed it